Revolution Medicines' Rasonque (Daraxonrasib) Wins Historic FDA Approval for Pancreatic Cancer
On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque™ (daraxonrasib), developed by Revolution Medicines, Inc., as a once-daily oral targeted therapy for adults with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations.
The approval represents a major clinical and regulatory breakthrough, doubling overall survival rates in a highly lethal disease and achieving authorization months ahead of schedule through the FDA's controversial FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months.
Clinical Efficacy: Doubling Survival in a Lethal Cancer
The approval was based on results from the international, randomized Phase III RASolute 302 trial (NCT06625320), which evaluated daraxonrasib (formerly RMC-6236) in 500 patients across 59 global sites. The trial demonstrated that daraxonrasib:
- Doubled Overall Survival (OS): Patients receiving the once-daily oral tablet showed a two-fold increase in median overall survival compared to standard-of-care salvage chemotherapy.
- Doubled Progression-Free Survival (PFS): The therapy significantly extended the time patients lived without their disease worsening.
- Favorable Safety Profile: Daraxonrasib was well-tolerated with a manageable safety profile, offering a major quality-of-life improvement over traditional cytotoxic chemotherapy.
Regulatory Acceleration via the CNPV Program
Rasonque was approved 6.5 months ahead of its standard PDUFA user fee deadline. This rapid approval was enabled by the drug's review under the FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program, which targets a 1-to-2-month review timeline for therapies addressing critical national public health needs. Revolution Medicines had initially been granted the priority voucher in October 2025 and filed its New Drug Application (NDA) just weeks before the final approval was granted.
Market Impact and Commercial Outlook
Wall Street analysts and oncology experts have heralded the approval as a "grand slam." Because of its potential to treat a wide array of RAS-mutated solid tumors, analysts project peak annual sales for Rasonque could reach $11.5 billion. Revolution Medicines is also evaluating the drug in an ongoing Phase III trial for non-small cell lung cancer (NSCLC).
However, the drug's pricing has already sparked debate. Rasonque is priced at $480,000 per year (approximately $40,000 per month), reflecting the high commercial premiums commanded by modern breakthrough oncology therapies and highlighting the ongoing tension between rapid innovation and patient affordability.